Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Edgewise Therapeutics (EWTX) Return on Capital Employed (2021 - 2026)

Edgewise Therapeutics has reported Return on Capital Employed over the past 6 years, most recently at 38.9% for Q1 2026.

  • Quarterly results put Return on Capital Employed at 38.9% for Q1 2026, down 107.0% from a year ago — trailing twelve months through Mar 2026 was 38.9% (down 107.0% YoY), and the annual figure for FY2025 was 38.88%, up 189.0%.
  • Return on Capital Employed reached 38.9% in Q1 2026 per EWTX's latest filing, down from 35.4% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 19.03% in Q1 2022 and bottomed at 38.9% in Q1 2026.
  • Median Return on Capital Employed over the past 5 years was 29.28% (2024), compared with a mean of 29.39%.
  • The largest annual shift saw Return on Capital Employed tumbled -1686bps in 2023 before it skyrocketed 438bps in 2024.
  • Over 5 years, Return on Capital Employed stood at 20.15% in 2022, then crashed by -84bps to 37.02% in 2023, then increased by 10bps to 33.42% in 2024, then fell by -6bps to 35.4% in 2025, then fell by -10bps to 38.9% in 2026.
  • Business Quant data shows Return on Capital Employed for EWTX at 38.9% in Q1 2026, 35.4% in Q4 2025, and 31.38% in Q3 2025.